Alitretinoin

Generic Name
Alitretinoin
Brand Names
Panretin
Drug Type
Small Molecule
Chemical Formula
C20H28O2
CAS Number
5300-03-8
Unique Ingredient Identifier
1UA8E65KDZ
Background

An important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute).

Indication

外用可用于局部治疗艾滋病相关的卡波西肉瘤且未接受全身治疗的皮肤损伤。口服可用于局部外用强效糖皮质激素无效的慢性手部湿疹患者。

Associated Conditions
Chronic Eczema of the hand, Cutaneous lesions, Refractory Eczema of the hand, Severe Eczema of the hand
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Phase 3
Completed
Conditions
Hand Dermatoses
First Posted Date
2006-04-03
Last Posted Date
2023-05-10
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
250
Registration Number
NCT00309621
Locations
🇩🇪

Abt. Klinische Sozialmedizin, Heidelberg, Germany

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

Phase 3
Completed
Conditions
Hand Dermatoses
First Posted Date
2005-07-28
Last Posted Date
2023-05-10
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
300
Registration Number
NCT00124436
Locations
🇩🇪

Thomas Ruzicka, Düsseldorf, Germany

Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Phase 3
Completed
Conditions
Hand Dermatoses
First Posted Date
2005-07-28
Last Posted Date
2023-05-10
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
1035
Registration Number
NCT00124475
Locations
🇩🇪

Thomas Ruzicka, MD, Düsseldorf, Germany

A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma

Phase 2
Completed
Conditions
Sarcoma, Kaposi
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Anderson Clinical Research
Target Recruit Count
27
Registration Number
NCT00002188

A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

Not Applicable
Completed
Conditions
Sarcoma, Kaposi
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Anderson Clinical Research
Registration Number
NCT00002439

A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients

Phase 1
Completed
Conditions
Breast Cancer
Breast Neoplasm
First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
18
Registration Number
NCT00001504
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy